Literature DB >> 16517208

Sickle cell disease and nitric oxide: a paradigm shift?

A Kyle Mack1, Gregory J Kato.   

Abstract

Traditionally the pathophysiology of sickle cell disease is thought to result from the polymerization of hemoglobin S in red cells, under hypoxic conditions, resulting in the occlusion of blood vessels. Adhesion of cells to the venular endothelium also appears to play a role. Recent studies have also suggested that in addition to the polymerization of hemoglobin S in the red blood cell, a deficiency of the endogenous vasodilator, nitric oxide may be involved. Hemoglobin released as a result of hemolysis rapidly consumes nitric oxide resulting in a whole program of events that inhibit blood flow. Therapies directed at decreasing the destruction of nitric oxide, increasing the production of nitric oxide, or amplifying the nitric oxide response may prove beneficial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517208      PMCID: PMC2199240          DOI: 10.1016/j.biocel.2006.01.010

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  36 in total

Review 1.  Reactive species in sickle cell disease.

Authors:  M Aslan; D Thornley-Brown; B A Freeman
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Authors:  M Aslan; T M Ryan; B Adler; T M Townes; D A Parks; J A Thompson; A Tousson; M T Gladwin; R P Patel; M M Tarpey; I Batinic-Haberle; C R White; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

4.  Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation.

Authors:  L Belhassen; G Pelle; S Sediame; D Bachir; C Carville; C Bucherer; C Lacombe; F Galacteros; S Adnot
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Authors:  Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

6.  Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease.

Authors:  Debra L Weiner; Patricia L Hibberd; Peter Betit; Andrew B Cooper; Christine A Botelho; Carlo Brugnara
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

7.  Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.

Authors:  C R Morris; F A Kuypers; S Larkin; E P Vichinsky; L A Styles
Journal:  J Pediatr Hematol Oncol       Date:  2000 Nov-Dec       Impact factor: 1.289

8.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

9.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.

Authors:  Vladan P Cokic; Reginald D Smith; Bojana B Beleslin-Cokic; Joyce M Njoroge; Jeffery L Miller; Mark T Gladwin; Alan N Schechter
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

10.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

View more
  38 in total

1.  Leg ulcers in sickle cell disease.

Authors:  Caterina P Minniti; James Eckman; Paola Sebastiani; Martin H Steinberg; Samir K Ballas
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

2.  Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain.

Authors:  Maha Khaleel; Mammen Puliyel; Payal Shah; John Sunwoo; Roberta M Kato; Patjanaporn Chalacheva; Wanwara Thuptimdang; Jon Detterich; John C Wood; Jennie Tsao; Lonnie Zeltzer; Richard Sposto; Michael C K Khoo; Thomas D Coates
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

Review 3.  Antibiotics for treating acute chest syndrome in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno; Jennifer M Knight-Madden
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

Review 4.  Pediatric sickle cell disease: past successes and future challenges.

Authors:  Emily Riehm Meier; Angeli Rampersad
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

Review 5.  L-glutamine for sickle cell disease: Knight or pawn?

Authors:  Alina Sadaf; Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-27

Review 6.  Antibiotics for treating osteomyelitis in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Luis H Agreda-Pérez
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

7.  Study of correlation of nitrite levels with malonaldehyde and the prognosis of patients with sickle cell disease on hydroxyurea, Ceará-Brazil.

Authors:  Romélia Pinheiro Gonçalves; Darcielle Bruna Dias Elias; Hemerson Iury Ferreira Magalhães; Jacqueline Holanda de Souza
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

8.  Abnormal Regulation of Microvascular Tone in a Murine Model of Sickle Cell Disease Assessed by Contrast Ultrasound.

Authors:  Melinda D Wu; J Todd Belcik; Yue Qi; Yan Zhao; Cameron Benner; Hong Pei; Joel Linden; Jonathan R Lindner
Journal:  J Am Soc Echocardiogr       Date:  2015-06-27       Impact factor: 5.251

9.  Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients.

Authors:  Oluwagbemiga O Ayoola; Rahman A Bolarinwa; Uvie U Onakpoya; Tewogbade A Adedeji; Chidiogo C Onwuka; Bukunmi M Idowu
Journal:  Blood Adv       Date:  2018-11-27

Review 10.  Nitrite as regulator of hypoxic signaling in mammalian physiology.

Authors:  Ernst E van Faassen; Soheyl Bahrami; Martin Feelisch; Neil Hogg; Malte Kelm; Daniel B Kim-Shapiro; Andrey V Kozlov; Haitao Li; Jon O Lundberg; Ron Mason; Hans Nohl; Tienush Rassaf; Alexandre Samouilov; Anny Slama-Schwok; Sruti Shiva; Anatoly F Vanin; Eddie Weitzberg; Jay Zweier; Mark T Gladwin
Journal:  Med Res Rev       Date:  2009-09       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.